1. The role of immune checkpoint inhibitors and/or Yttrium-90 radioembolization in the management of hepatocellular carcinoma: challenges of treatment sequence
   Samantha M. Ruff et al, 2024, Hepatoma Research CrossRef
2. Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies
   Tao Ouyang et al, 2022, Frontiers in Oncology CrossRef
3. A Trinity Nano-Vaccine System with Spatiotemporal Immune Effect for the Adjuvant Cancer Therapy after Radiofrequency Ablation
   Minghui Li et al, 2024, ACS Nano CrossRef
4. Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go
   Kunpeng Wang et al, 2021, Frontiers in Immunology CrossRef
5. Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study
   Masatoshi Kudo et al, 2023, Liver Cancer CrossRef
6. Thermal ablation and immunotherapy for hepatocellular carcinoma: Recent advances and future directions
   Xiao-Wan Bo et al, 2021, World Journal of Gastrointestinal Oncology CrossRef
7. Current status and perspectives of immune-based therapies for hepatocellular carcinoma
   Maridi Aerts, 2016, World Journal of Gastroenterology CrossRef
8. Immunotherapy for hepatocellular carcinoma: Current and future
   Michael P Johnston et al, 2019, World Journal of Gastroenterology CrossRef
9. Distinct Gene Expression Profiles in Viable Hepatocellular Carcinoma Treated With Liver-Directed Therapy
   Kelley G. Núñez et al, 2022, Frontiers in Oncology CrossRef
10. PD-1 expression in hepatocellular carcinoma predicts liver-directed therapy response and bridge-to-transplant survival
    Kelley G. Núñez et al, 2022, Cancer Immunology, Immunotherapy CrossRef
11. Microwave ablation combined with apatinib and camrelizumab in patients with advanced hepatocellular carcinoma: A single-arm, preliminary study
    Xin Li et al, 2022, Frontiers in Immunology CrossRef
12. Potentiality of immunotherapy against hepatocellular carcinoma
    Nobuhiro Tsuchiya, 2015, World Journal of Gastroenterology CrossRef
13. Prospects for immunotherapy as a novel therapeutic strategy against hepatocellular carcinoma
    Yu Akazawa et al, 2019, World Journal of Meta-Analysis CrossRef
14. Radiofrequency ablation plays double role in immunosuppression and activation of PBMCs in recurrent hepatocellular carcinoma
    Yang Zhao et al, 2024, Frontiers in Immunology CrossRef
15. Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
    Yu Sawada et al, 2016, OncoImmunology CrossRef
16. Combinatory local ablation and immunotherapies for hepatocellular carcinoma: Rationale, efficacy, and perspective
    Shuling Chen et al, 2022, Frontiers in Immunology CrossRef
17. In-situ tumor vaccination by percutaneous ablative therapy and its synergy with immunotherapeutics: An update on combination therapy
    Nicole J. Kim et al, 2023, Frontiers in Immunology CrossRef
18. Circulating biomarkers of hepatocellular carcinoma response after locoregional treatments: New insights
    Maria Tampaki, 2015, World Journal of Hepatology CrossRef
19. Anti-tumor effects of nanosecond pulsed electric fields in a murine model of pancreatic cancer
    Yuan-yuan Liang et al, 2025, Bioelectrochemistry CrossRef
20. Identification of Gene-Set Signature in Early-Stage Hepatocellular Carcinoma and Relevant Immune Characteristics
    Qijie Zhao et al, 2021, Frontiers in Oncology CrossRef
21. Emerging data on immune checkpoint inhibitors in the neoadjuvant and adjuvant setting for patients with hepatocellular carcinoma
    Samantha M. Ruff et al, 2024, Hepatoma Research CrossRef